Hummingbird Bioscience
https://www.hummingbirdbioscience.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hummingbird Bioscience
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
Merck KGaA Looks To Build Cancer ADCs With Caris’s AI Technology
Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Singapore: A Country Punching Above Its Weight
With strong government support over the past two decades, the Singaporean life sciences industry has matured. Initially known as a manufacturing hub, Singapore’s innovation ecosystem is now thriving, but the challenge is to cultivate commercialization power.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice